Skip to main content

Actions to strengthen presence in North Africa : Congress & Surgeons trainings

Press release        Ecully, June 18, 2024 – 6 p.m.

Presentation of the KAPHORN system to 200 surgeons
at the SOTCOT Congress in Hammamet

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, was represented at the 39th edition of the Tunisian Orthopedic Society (SOTCOT) Congress, held from June 6 to 8 in Hammamet, Tunisia.

Dr. Radwan Hilmi (Head of Orthopedics and Traumatology Department at Hôpital Nord Ouest, Villefranche-sur-Saône), co-designer and user of the KAPHORN arthrodesis system, was invited by Pr Chebbi (Professor of Orthopaedic and Spinal Surgery at Centre de traumatologie et des grands brûlés, Tunis) to chair a symposium. In front of an audience of around 200 surgeons, Dr. Hilmi presented the technical features and advantages of Spineway’s KAPHORN system for the treatment of deformities and degenerative pathologies of the thoracolumbar spine.

During the congress, Dr Hilmi also conducted training sessions and workshops on the KAPHORN system for spinal surgeons, directly at the booth of MME Company, Spineway’s local partner and exclusive distributor in Tunisia. He also had the opportunity to have peer to peer discussions with the three Tunisian surgeons1 who attended Spineway’s international training program with Dr Sabatier – Clinique des Cèdres (Toulouse) in early May.2 They shared their feedback, ensuring continuity in the training of international surgeons.

The event will enable Spineway to strengthen its presence in North Africa while developing training on its implant systems to increase the technical expertise of new users. Exchanges and the sharing of experience between international surgeons and French surgeons contribute actively to the development of the reputation of the Group’s products.

Next event:
July 15, 2024 – H1 2024 revenue

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of independent distributors and derives more than 70% of its revenue from exports.
ISIN: FR001400BVK2 – ALSPW        

Contacts:

SPINEWAY GROUP

Shareholder-services line

Available Tuesday through Thursday

+33 (0)806 706 060

ELIGIBLE PEA / PME

ALSPW

EURONEXT GROWTH

AELIUM

Finance & Communication

Investor relations

Solène Kennis

spineway@aelium.fr


1 Pr BARSAOUI:  (Head of Department, RABTA Hospital), Pr BEN SALAH: (Deputy Head of Departmentat Charles Nicolle Hospital) and Dr AKREMI:  (Assistant Professor at Hôpital Charles Nicolle).
2 Press release of May 30, 2024

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.